Exelixis cuts 10% of staff
This article was originally published in Scrip
Exelixis is making 78 employees redundant, 10% of its workforce, to bring its net cash burn in line with its cash position. The company said at its third-quarter results presentation that it would consider job cuts as part of a strategy to make it independent of capital markets for an extended period (Scrip Online, October 29th, 2008). The job losses are part of a restructuring plan for which Exelixis will record a $3.3 million charge in the fourth quarter.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.